Literature DB >> 2508821

Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly.

J A McKnight1, D R McCance, J G Crothers, A B Atkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2508821      PMCID： PMC1837463          DOI： 10.1136/bmj.299.6699.604

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  Cholecystectomy for gall stones.

Authors:  N Finlayson
Journal:  BMJ       Date:  1989-01-21

Review 2.  The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors.

Authors:  S W Lamberts
Journal:  Endocr Rev       Date:  1988-11       Impact factor: 19.871

3.  Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

Authors:  B Lembcke; W Creutzfeldt; S Schleser; R Ebert; C Shaw; I Koop
Journal:  Digestion       Date:  1987       Impact factor: 3.216

Review 4.  Glucagonomas, VIPomas and somatostatinomas.

Authors:  S R Bloom; J M Polak
Journal:  Clin Endocrinol Metab       Date:  1980-07
  4 in total
  13 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Gall stones and treatment with octreotide for acromegaly.

Authors: 
Journal:  BMJ       Date:  1989-11-04

3.  Changes in glucose tolerance after treatment for acromegaly.

Authors:  V Fonseca; P Dandona; C W Havard
Journal:  BMJ       Date:  1989-11-04

4.  Effect of octreotide on dynamic excretion of bile in Chinese acromegalic patients assessed by [99mTc]EHIDA hepatobiliary scan.

Authors:  X F Zhu; A G Harris; M F Yang; Y F Shi; Q Zhou; J Y Xu; J X Zhang
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

5.  Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.

Authors:  P Kendall-Taylor; M Miller; J Gebbie; S Turner; M al-Maskari
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

6.  Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.

Authors:  R Attanasio; A Mainolfi; F Grimaldi; R Cozzi; M Montini; C Carzaniga; S Grottoli; L Cortesi; M Albizzi; R M Testa; L Fatti; D De Giorgio; C Scaroni; F Cavagnini; P Loli; G Pagani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 7.  Use of octreotide acetate for control of symptoms in patients with islet cell tumors.

Authors:  P N Maton
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

Review 8.  Drug-induced gallbladder disease. Incidence, aetiology and management.

Authors:  P P Michielsen; H Fierens; Y M Van Maercke
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

9.  Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.

Authors:  M F Stolk; K J van Erpecum; H P Koppeschaar; W I de Bruin; J B Jansen; C B Lamers; G P van Berge Henegouwen
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

10.  Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment.

Authors:  W P Hopman; P A Van Liessum; G F Pieters; J B Jansen; C B Lamers; A G Smals; G Rosenbusch; P W Kloppenborg
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.